425: Waters Corporation to Acquire BD's Biosciences & Diagnostic Solutions Business, Targeting High-Growth Markets

Waters Corporation announces its planned acquisition of Becton, Dickinson and Company's Biosciences & Diagnostic Solutions business, aiming to diversify revenue and accelerate expansion into bioseparations, bioanalytical characterization, and multiplex diagnostics.

Summary

• Waters Corporation is combining with BD's Biosciences & Diagnostic Solutions business.
• The acquisition aims to expand Waters' presence in high-growth adjacencies: bioseparations, bioanalytical characterization, and multiplex diagnostics.
• BD's Biosciences & Diagnostic Solutions business is a leader in upstream R&D and clinical diagnostics, including flow cytometry, microbiology, and molecular diagnostics.
• The combined company expects to welcome approximately 8,000 new colleagues.
• The transaction is expected to close around the end of the first quarter of calendar year 2026.
• Waters will be the acquiring entity, and its stock will continue to trade as usual.
• Waters shareholders will have an opportunity to vote on the transaction at a special meeting.
• The combined company will operate as Waters, with headquarters remaining in Milford, MA.
• Udit Batra will continue as CEO, and Amol Chaubal will serve as SVP and Chief Financial Officer.

Sentiment

Score: 8

Explanation: The document presents the acquisition as a highly strategic and beneficial move for Waters, emphasizing diversification, expansion into high-growth areas, and leveraging complementary strengths. While standard M&A risks are listed, the overall framing is optimistic and forward-looking, indicating a strong positive sentiment.

Positives

• Combines complementary, innovative technologies and commercial channels to better serve customer needs.
• Expected to diversify high-quality recurring revenue.
• Accelerates strategy to expand into multiple high-growth adjacencies, including bioseparations, bioanalytical characterization, and multiplex diagnostics.
• Leverages Waters' chemistry expertise with BD's biologics expertise to unlock new ways to separate large molecules and drive growth in biologics.
• Deploys BD's flow cytometry technology into large molecule QA/QC by leveraging Waters' expertise in downstream high-volume applications and Empower.
• BD's regulatory expertise and established presence in clinical and diagnostic settings are expected to drive enhanced market access, improved service support, and accelerated menu expansion and automation for LC-MS instrumentation.
• BD's Biosciences is a leader in immunology and cancer research solutions, flow cytometry instruments and reagents, and innovative multiomics tools.
• BD's Diagnostic Solutions is a leader in microbiology and infectious disease diagnostics, including molecular diagnostics, cervical cancer screening, and microbiology automation.
• Expected to create more and differentiated development opportunities for employees across the combined company.
• The combined company will have a comprehensive platform with leading technologies across liquid chromatography, mass spectrometry, flow cytometry, and diagnostic solutions.

Risks

• One or more closing conditions to the transaction, including certain regulatory approvals, may not be satisfied or waived on a timely basis or otherwise.
• A governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the proposed transaction, or may require conditions, limitations, or restrictions.
• The required approval by the stockholders of Waters may not be obtained.
• The proposed transaction may not be completed on the terms or in the time frame expected, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty of the expected financial performance of the combined company following completion of the proposed transaction.
• Failure to realize the anticipated benefits of the proposed transaction, including as a result of delay in completing the proposed transaction or integrating the businesses.
• Difficulties and delays in the combined company achieving revenue and cost synergies.
• Inability of the combined company to retain and hire key personnel.
• The occurrence of any event that could give rise to termination of the proposed transaction.
• Stockholder litigation in connection with the proposed transaction or other litigation, settlements, or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs.
• Evolving legal, regulatory, and tax regimes.
• Changes in general economic and/or industry-specific conditions or any volatility resulting from the imposition of and changing policies around tariffs.
• Actions by third parties, including government agencies.
• The risk that the anticipated tax treatment of the proposed transaction is not obtained.
• The risk of greater than expected difficulty in separating the business of SpinCo from the other businesses of BD.
• Risks related to the disruption of management time from ongoing business operations due to the pendency of the proposed transaction.
• Other effects of the pendency of the proposed transaction on the relationship of any of the parties to the transaction with their employees, customers, suppliers, or other counterparties.

Future Outlook

The combined company expects to further diversify high-quality recurring revenue and accelerate its strategy to expand into high-growth adjacencies, including bioseparations, bioanalytical characterization, and multiplex diagnostics. Waters plans to apply its expertise in instrument replacement, service plan attachment, and e-commerce adoption to BD's Biosciences & Diagnostic Solutions business to help it realize its full potential.

Management Comments

• When BD announced its plan to divest its Biosciences & Diagnostic Solutions business in February, we knew it was an asset that would fit well within Waters.
• Bringing together our complementary, innovative technologies and commercial channels will better position the combined company to serve customers unmet needs across high-volume, regulated settings in large and attractive end-markets.
• We expect the combined business to further diversify our high-quality recurring revenue and accelerate our strategy to expand into multiple high-growth adjacencies.
• As we become a larger, more diversified innovator in the industry, we expect more and differentiated development opportunities for employees across the combined company.
• We expect to complete the transaction around the end of the first quarter of calendar year 2026, subject to receipt of required regulatory approvals, Waters shareholder approval, and satisfaction of other customary closing conditions.
• Until then, both organizations will continue to operate independently, and it remains business as usual for all of us.
• Udit Batra will continue to lead the company as CEO. Amol Chaubal will serve as SVP and Chief Financial Officer.
• Combining with BDs Biosciences & Diagnostic Solutions business will advance the strategy we have been focused on for the past few years to expand into high-growth adjacencies.
• We are committed to transparency and will keep you informed as we have updates to share.
• Customers remain a top priority, and we look forward to being able to serve them with a broader portfolio.

Industry Context

The acquisition reflects a trend towards consolidation and expansion into specialized, high-growth areas within the life sciences and diagnostics sectors. Companies are seeking to broaden their portfolios and leverage complementary technologies to address complex research and clinical needs, particularly in areas like immunology, oncology, cell therapy, and infectious disease diagnostics. The focus on 'high-volume, regulated settings' and 'next-generation consumables' indicates a strategic move towards integrated solutions and recurring revenue streams, aligning with broader industry shifts.

Comparison to Industry Standards

• BD's Biosciences & Diagnostic Solutions is described as a 'leader' in cellular analysis, immunology, cancer research, flow cytometry, microbiology, and infectious disease diagnostics, implying strong market positions and competitive offerings.
• The combination aims to leverage 'breakthrough technologies' and 'differentiated technology' from BD, suggesting a competitive edge in specific segments like single cell multiomics and molecular testing for women's health.
• The strategy to expand into bioseparations, bioanalytical characterization, and multiplex diagnostics aligns with broader industry trends of precision medicine, advanced analytical techniques, and the increasing demand for integrated diagnostic solutions.
• The document does not provide specific comparable companies or projects with numerical results for direct comparison of performance metrics.

Management Changes

Legal Proceedings

• Risk of stockholder litigation in connection with the proposed transaction or other litigation, settlements, or investigations that may affect the timing or occurrence of the proposed transaction or result in significant costs.

Stakeholder Impact

• Shareholders: Waters shareholders will vote on the transaction and their stock will continue to trade. The transaction is expected to create long-term value through diversification and expansion into high-growth areas.
• Employees: Approximately 8,000 new colleagues will be welcomed. Expected more and differentiated development opportunities. Potential for changes in roles/responsibilities post-close as part of integration planning.
• Customers: Expected to be better served with a broader portfolio and comprehensive platform, accelerating innovation in key areas.
• Suppliers/Creditors: Potential for disruption to relationships due to the pendency of the proposed transaction.

Next Steps

• Both organizations will continue to operate independently until the transaction closes.
• A dedicated team of leaders from both businesses will work together to develop integration plans.
• Waters will keep employees informed about any changes to organizational structures and reporting lines.
• Waters shareholders will have an opportunity to vote for the transaction at a special meeting.
• Relevant materials, including a registration statement on Form S-4 and Form 10, will be filed with the SEC.
• Investors and security holders are urged to read the proxy statement/prospectus and other documents filed with the SEC.

Key Dates

Recommendation

Keywords

Waters Corporation, Becton Dickinson, BD, Biosciences, Diagnostic Solutions, acquisition, merger, life sciences, diagnostics, flow cytometry, microbiology, molecular diagnostics, bioseparations, bioanalytical characterization, multiplex diagnostics, laboratory equipment, analytical instruments, healthcare, R&D, clinical diagnostics